Table 2.
Proteins from which abundant HLA ligands were repeatedly found
| Source protein overexpression > threefold in X/11 RCCs | Entrez Gene ID | Peptides found on X/13 tumors | Sequence | HLA restriction |
|---|---|---|---|---|
| Vimentin (VIM) 6/11 (M 3.5; R 0.2–6.4) | 7431 | 8 | ALRDVRQQY | B*1501 |
| ALRPSTSRSLY | A*03 | |||
| DLERKVESL [11] | A*0201 | |||
| EEIAFLKKL [56] | B*18 | |||
| EENFAVEA | B*45 | |||
| MEENFAVEA | B*45 | |||
| NLRETNLDSLP | NA | |||
| NYIDKVRFL | A*24 | |||
| REKLQEEML | B*40 | |||
| RETNLDSLP | NA | |||
| SLYASSPGGVYATR | A*03 | |||
| SRISLPLPNF | B*27 | |||
| SSVPGVRLLQDSVDF | NA | |||
| SSVPGVRLLQDSVDFSL | NA | |||
| Adipose differentiation-related protein (ADFP) 5/11 (M 2.6; R 0.1–5.5) | 123 | 5 | IARNLTQQL | B*07 |
| MAGDIYSVFR [56] | A*6801 | |||
| MTSALPIIQK [56] | A*6801 | |||
| SLLTSSKGQLQK | A*03 | |||
| SVASTITGV [56] | A*0201 | |||
| TSALPIIQK | A*03 | |||
| VQKPSYYVR | A*31 | |||
| Actin, beta (ACTB) 0/11 (M 0.8; R 0.6–2.5) | 60 | 4 | LRVAPEEHPVL | NA |
| MEKIWHHTF | B*18 | |||
| MQKEITAL | B*1501 | |||
| RVAPEEHPV | A*02 | |||
| RVAPEEHPVL | A*02 | |||
| RVAPEEHPVLLT | A*02 | |||
| Spectrin beta, non-erythrocytic 1 (SPTBN1) 0/11 (M 0.8; R 0.5–2.1) | 6711 | 5 | AVCEVALDY | NA |
| DEKSIITY | B*18 | |||
| DEMKVLVL [56] | B*18 | |||
| EEASLLHQF | B*44 | |||
| KPRDVSSVEL | B*07 | |||
| Myosin light chain alkali non-muscle isoform (MYL6) 0/11 (M 0.7; R 0.4–1.0) | 4637 | 4 | AEIRHVLVTL | B*40 |
| EAFVRHIL | B*08 | |||
| LVRMVLNG | NA | |||
| YEELVRMVL | B*40 | |||
| Catenin (cadherin-associated protein), alpha 1 (CTNNA1) 0/11 (M 0.8; R 0.5–1.1) | 1495 | 3 | FIDASRLVY | A*01 |
| LQHPDVAAY | B*1501 | |||
| NEQDLGIQY [56] | B*44/B*18 | |||
| Spectrin alpha, non-erythrocytic 1 (SPTAN1) 0/11 (M 0.8; R 0.6–1.5) | 6709 | 3 | ADSLRLQQL | B*37 |
| ETFDAGLQAF | A*25 | |||
| RQGFVPAAY | B*1501 |
M median; R range of overexpression
NA not assigned